Drug news
Xarelto (Bayer/Janssen) is FDA filed for Acute Coronary Syndrome
Bayer HealtCare and Janssen Pharmaceuticals have submitted a supplemental New Drug Application to the FDA seeking approval for the use of Xarelto (rivaroxaban) to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome.The application is based on the ATLAS ACS 2-TIMI 51 study,
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.